Ceramic/polymer nanocomposites with tunable drug delivery capability at specific disease sites

Journal of Biomedical Materials Research - Part A

Volumn 93, Issue 3, 2010, Pages 1180-1192

  Liu, Huinan ^a   Webster, Thomas J ^a  

^a Brown University   (United States)

Author keywords

Biodegradable polymer; Bone diseases; Controlled drug delivery; Hydroxyapatite; Nanocomposite; Orthopedic dental applications; Peptide delivery; PLGA; Prolonged drug release; Protein delivery

Indexed keywords

BONE DISEASE; BONE DISEASES; DRUG RELEASE; PEPTIDE DELIVERY; PROLONGED DRUG RELEASE; PROTEIN DELIVERY;

ADSORPTION; APATITE; BIODEGRADABLE POLYMERS; BIOMATERIALS; BONE; GROWTH (MATERIALS); HYDROXYAPATITE; HYDROXYLATION; NANOCOMPOSITES; PEPTIDES;

CONTROLLED DRUG DELIVERY;

DIF 7C; DRUG CARRIER; NANOCOMPOSITE; NANOCRYSTALLINE HYDROXYAPATITE; PEPTIDE DERIVATIVE; POLYMER; POLYMER(POLY LACTIDE CO GLYCOLIDE); SILANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; BONE DISEASE; BONE GROWTH; BONE REGENERATION; CALVARIA; CERAMICS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

ANIMALS; BENZOATES; BONE DISEASES; CERAMICS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LACTIC ACID; NANOCOMPOSITES; PEPTIDES; POLYGLYCOLIC ACID; QUINOLINES; RATS;

EID: 77950681035     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32614     Document Type: Article

References (50)

1. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004.
2. Hollander AP, Dickinson SC, Sims TJ, Brun P, Cortivo R, Kon E, Marcacci M, Zanasi S, Borrione A, De Luca C, Pavesio A, Soranzo C, Abatangelo G. Maturation of tissue engineered cartilage implanted in injured and osteoarthritic human knees. Tissue Eng 2006;12:1787-1798. (Pubitemid 44162838)
3. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379.
4. Miyai T, Ito A, Tamazawa G, Matsuno T, Sogo Y, Nakamura C, Yamazaki A, Satoh T. Antibiotic-loaded poly-epsilon-caprolactone and porous beta-tricalcium phosphate composite for treating osteomyelitis. Biomaterials 2008;29:350-358. (Pubitemid 350060982)
5. Dash AK, Suryanarayanan R. An implantable dosage form for the treatment of bone infections. Pharm Res 1991;9:993-1002.
6. Pham HH, Luo P, Génin F, Dash AK. Synthesis and characterization of hydroxyapatite-ciprofloxacin delivery systems by precipitation and spray drying technique. AAPS PharmSci-Tech 2002;3:E1. (Pubitemid 41086089)
7. Ferraz MP, Mateus AY, Sousa JC, Monteiro FJ. Nanohydroxyapatite microspheres as delivery system for antibiotics: Release kinetics, antimicrobial activity, and interaction with osteoblasts. J Biomed Mater Res A 2007;81:994-1004.
8. Kim HW, Knowles JC, Kim HE. Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery. Biomaterials 2004;25:1279-1287. (Pubitemid 37476205)
9. Liu H, Slamovich EB, Webster TJ. Increased osteoblast functions among nanophase titania/poly(lactide-co-glycolide) composites of the highest nanometer surface roughness. J Biomed Mater Res A 2006;78:798-807. (Pubitemid 44300034)
10. Ergun C, Liu H, Halloran JW, Webster TJ. Increased osteoblast adhesion on nanograined hydroxyapatite and tricalcium phosphate containing calcium titanate. J Biomed Mater Res A 2007;80:990-997. (Pubitemid 46310003)
11. Liu H. Design, fabrication and evaluation of 2D to 3D nano-structured ceramic/polymer composites for orthopedic regeneration and controlled drug delivery, Ph.D. Dissertation. Providence, RI: Brown University; 2008.
12. Webster TJ, Ergun C, Doremus RH, Siegel RW, Bizios R. Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials 2000;21:1803-1810. (Pubitemid 30365044)
13. Li P. Biomimetic nano-apatite coating capable of promoting bone ingrowth. J Biomed Mater Res 2003;66:79-85. (Pubitemid 37517253)
14. Liu H, Webster TJ. Nanomedicine for implants: A review of studies and necessary experimental tools. Biomaterials 2006;28:354-369. (Pubitemid 44540373)
15. Balasundaram G, Webster TJ. Nanotechnology and biomaterials for orthopedic medical applications. Nanomedicine 2006;1:169-176.
16. Koempel JA, Patt BS, O'grady K, Wozney J, Toriumi DM. Effect of recombinant human bone morphogenetic protein-2 on the integration of porous hydroxyapatite implants with bone. J Biomed Mater Res 1998;41:359-363.
17. Alam MI, Asahina I, Ohmamiuda K, Takahashi K, Yokota S, Enomoto S. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials 2001;22:1643-1651. (Pubitemid 32551915)
18. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kritz RW, Hewick RM, Wang EA. Novel regulators of bone formation: Molecular clones and activity. Science 1988;242:1528-1534. (Pubitemid 19023695)
19. Wang EA, Rosen V, D'alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg DP, McQuaid D, Moutsatsos IK, Nove J, Wozney JM. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990;87:2220-2224.
20. Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ, Suda T, Yoshiki S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 1991;113:681-687. (Pubitemid 21926024)
21. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wozney JM, Wang EA. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomedical study in rats. J Bone Joint Surg Am 1992;74:659-670.
22. Miller TA, Ishida K, Kobayashi M, Wollman JS, Turk AE, Holmes RE. The induction of bone by an osteogenic protein and the conduction of bone by porous hydroxyapatite: A laboratory study in the rabbit. Plast Reconstr Surg 1991;87:87-95.
23. Toriumi DM, Kotler HS, Luxenberg DP, Holtrop ME, Wang EA. Mandibular reconstruction with a recombinant bone-inducing factor: Functional, histologic, and biomechanical evaluation. Arch Otolaryngol Head Neck Surg 1991;117:1101-1112.
24. Gerhart TN, Kirker-Head CA, Kriz MJ, Holtrop ME, Hennig GE, Hipp J, Schelling SH, Wang E. Healing of segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Relat Res 1993;293:317-326. (Pubitemid 23242887)
25. Aebli N, Stich H, Schawalder P, Theis JC, Krebs J. Effects of bone morphogenetic protein-2 and hyaluronic acid on the osseointegration of hydroxyapatite-coated implants: An experimental study in sheep. J Biomed Mater Res 2005;73:295-302. (Pubitemid 40664295)
26. Dellinger JG, Eurell JAC, Jamison RD. Bone response to 3D periodic hydroxyapatite scaffolds with and without tailored microporosity to deliver bone morphogenetic protein 2. J Biomed Mater Res 2006;76:366-376.
27. Kaito T, Myoui A, Takaoka K, Saito N, Nishikawa M, Tamai N, Ohgushi H, Yoshikawa H. Potentiation of the activity of bone morphogenetic protein-2 in bone regeneration by a PLAPEG/hydroxyapatite composite. Biomaterials 2005;26:73-79. (Pubitemid 38759473)
28. Chao EY, Inoue N, Elias JJ, Aro H. Enhancement of fracture healing by mechanical and surgical intervention. Clin Orthop Relat Res 1998;355:S163-S178. (Pubitemid 28538529)
29. Minamide A, Kawakami M, Hashizume H, Sakata R, Tamaki T. Evaluation of carriers of bone morphogenetic protein for spinal fusion. Spine 2001;26:933-939. (Pubitemid 32373980)
30. Ribeiro CC, Barrias CC, Barbosa MA. Calcium phosphate-alginate microspheres as enzyme delivery matrices. Biomaterials 2004;25:4363-4373.
31. Bishop GB, Einhorn TA. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007;31:721-727.
32. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, Mckee MD. Clinical applications of BMP-7/OP-1 in fractures, non-unions and spinal fusion. Int Orthop 2007;31:735-741.
33. Chubinskaya S, Hurtig M, Rueger DC. OP-1/BMP-7 in cartilage repair. Int Orthop 2007;31:773-781.
34. Gautschi OP, Frey SP, Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J Surg 2007;77:626-631. (Pubitemid 47063348)
35. Pecina M, Giltaij LR, Vukicevic S. Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 2001;25:203-208. (Pubitemid 32802258)
36. Chen Y, Webster TJ. Increased osteoblast functions in the presence of BMP-7 short peptides for nanostructured biomaterial applications. J Biomed Mater Res A 2009;91:296-304.
37. Sato M, Sambito MA, Aslani A, Kalkhoran NM, Slamovich EB, Webster TJ. Increased osteoblast functions on undoped and yttrium-doped nanocrystalline hydroxyapatite coatings on titanium. Biomaterials 2006;27:2358-2369. (Pubitemid 41823951)
38. Ioku K, Yoshimura M. Stoichiometric apatite fine single crystals by hydrothermal synthesis. Phosphorus Res Bull 1991;1:15-20.
39. Somiya S, Ioku K, Yoshimura M. Hydrothermal synthesis and characterization of fine apatite crystals. Mater Sci Forum 1988;34:371-378.
40. Hong HG, Jiang M, Sligar SG, Bohn PW. Cysteine-specific surface tethering of genetically engineered cytochromes for fabrication of metalloprotein nanostructures. Langmuir 1994;10:153-158.
41. Balasundaram G, Sato M, Webster TJ. Using hydroxyapatite nanoparticles and decreased crystallinity to promote osteoblast adhesion similar to functionalizing with RGD. Biomaterials 2006;27:2798-2805. (Pubitemid 43165748)
42. Liu JP, Shirota O, Novotny M. Capillary electrophoresis of amino sugars with laser-induced fluorescence detection. Anal Chem 1991;63:413-417.
43. Instructions for Micro BCA™ Protein Assay Kit. Pierce. Also available at http://www.piercenet.com/files/0412dh5.pdf.
44. Liu H, Slamovich EB, Webster TJ. Less harmful acidic degradation of poly(lacticco-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. Int J Nanomedicine 2006;1:541-545.
45. Zhang R, Ma PX. Degradation behavior of porous poly (α-hydroxy acid)/hydroxyapatite composite scaffolds. Polym Prepr 2000;41:1618-1619.
46. Khang G, Rhee JM, Jeong JK, Lee JS, Kim MS, Cho SH, Lee HB. Local drug delivery system using biodegradable polymers. Macromol Res 2003;11:207-223. (Pubitemid 37373942)
47. Liu TY, Chen SY, Liu DM, Liou SC. On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. J Control Release 2005;107:112-121. (Pubitemid 41253707)
48. Genin FY, Luo P, Dash AK. Hydroxyapatite Based Drug Delivery Implant for Cancer Treatment. U.S. Pat. 6,767,550, 2004.
49. Cosijns A, Vervaet C, Luyten J, Mullens S, Siepmann F, Van Hoorebeke L, Masschaele B, Cnudde V, Remon JP. Porous hydroxyapatite tablets as carriers for low-dosed drugs. Eur J Pharm Biopharm 2007;67:498-506. (Pubitemid 47225041)
50. Ferraz MP, Mateus AY, Sousa JC, Monteiro FJ. Nanohydroxyapatite microspheres as delivery system for antibiotics: Release kinetics, antimicrobial activity, and interaction with osteoblasts. J Biomed Mater Res 2007;81:994-1004.